Live Earnings Conference Call: Lexicon Pharmaceuticals will host a live Q1 2026 earnings call on May 7, 2026 at 8:30AM ET. Get details.

Lexicon Pharmaceuticals (LXRX) Financials

$1.60 -0.05 (-3.03%)

Closing price 05/6/2026 04:00 PM Eastern

Extended Trading

$1.63 +0.03 (+1.87%)

As of 05/6/2026 07:59 PM Eastern

Compare

Annual Income Statements for Lexicon Pharmaceuticals

This table shows Lexicon Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-4.68	-131	-123	-120	130	-59	-88	-102	-177	-231	-50
Consolidated Net Income / (Loss)	-4.68	-131	-123	-121	130	-59	-88	-102	-177	-231	-50
Net Income / (Loss) Continuing Operations	-4.68	-131	-123	-121	130	-59	-87	-102	-177	-231	-54
Total Pre-Tax Income	-4.68	-131	-136	-121	124	0.00	-87	-104	-177	-231	-54
Total Operating Income	1.47	-127	-131	-103	141	-48	-87	-101	-172	-197	-49
Total Gross Profit	130	79	90	61	319	22	0.30	0.14	1.12	-0.62	144
Total Revenue	130	79	92	63	322	24	0.30	0.14	1.20	0.00	144
Operating Revenue	130	79	92	63	322	24	0.30	0.14	1.20	-	144
Total Cost of Revenue	0.00	0.00	1.90	2.49	3.23	1.93	0.00	0.00	0.09	0.62	0.27
Operating Cost of Revenue	0.00	0.00	1.90	2.49	3.23	1.93	0.00	0.00	0.09	0.62	0.27
Total Operating Expenses	129	206	220	164	177	70	87	101	173	243	205
Selling, General & Admin Expense	24	43	66	64	57	47	32	48	114	159	46
Research & Development Expense	95	164	152	100	92	154	55	53	59	84	61
Other Operating Expenses / (Income)	5.93	-0.70	2.10	-	-	-	-	-	-	-	99
Total Other Income / (Expense), net	-6.15	-4.27	-5.03	-17	-17	-11	0.13	-2.78	-5.37	12	7.07
Interest & Investment Income	-	-	-	-	-	-	-	-	-	-	0.16
Other Income / (Expense), net	0.57	2.29	1.95	3.51	3.35	2.77	0.13	-2.78	-5.37	12	6.91
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-	-	-	-0.21	-0.10	-	-	-	-	-	0.09
Basic Earnings per Share	($0.05)	($1.27)	($1.17)	($1.14)	$1.23	($0.53)	($0.60)	($0.62)	($0.80)	($0.63)	($0.14)
Weighted Average Basic Shares Outstanding	103.59M	103.86M	105.24M	105.83M	106.22M	110.84M	145.65M	165.73M	221.13M	320.03M	363.05M
Diluted Earnings per Share	($0.05)	($1.27)	($1.17)	($1.14)	$1.16	$0.00	($0.60)	($0.62)	($0.80)	($0.63)	($0.14)
Weighted Average Diluted Shares Outstanding	103.59M	103.86M	105.24M	105.83M	116.75M	0.00	145.65M	165.73M	221.13M	320.03M	363.05M
Weighted Average Basic & Diluted Shares Outstanding	103.59M	103.86M	105.24M	105.83M	144.35M	144.35M	-	-	246.24M	361.49M	423.68M

This table shows Lexicon Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-45	-51	-50	-48	-53	-65	-34	-25	3.25	-13	-16
Consolidated Net Income / (Loss)	-45	-51	-50	-48	-53	-65	-34	-25	3.25	-13	-16
Net Income / (Loss) Continuing Operations	-45	-51	-50	-48	-53	-65	-34	-25	3.25	-12	-20
Total Pre-Tax Income	-45	-51	-50	-48	-53	-65	-46	-25	3.25	-12	-20
Total Operating Income	-44	-50	-47	-45	-55	-64	-33	-26	3.74	-12	-15
Total Gross Profit	-0.01	0.16	0.97	1.10	1.48	1.68	26	1.23	29	42	73
Total Revenue	0.00	0.16	1.04	1.13	1.65	1.75	27	1.26	29	42	73
Operating Revenue	-	0.16	-	1.13	1.65	1.75	27	1.26	29	42	73
Total Cost of Revenue	0.01	0.01	0.07	0.03	0.17	0.07	0.35	0.03	0.03	0.01	0.20
Operating Cost of Revenue	0.01	0.01	0.07	0.03	0.17	0.07	0.35	0.03	0.03	0.01	0.20
Total Operating Expenses	45	50	47	46	57	65	59	27	25	55	99
Selling, General & Admin Expense	30	32	33	32	39	40	32	12	9.35	9.76	15
Research & Development Expense	15	18	15	14	18	26	27	15	16	19	11
Total Other Income / (Expense), net	-0.66	-0.89	-3.02	-3.06	1.93	-1.12	-13	0.38	-0.48	1.59	5.57
Other Income / (Expense), net	-0.66	-0.89	-3.02	-3.06	1.93	-1.12	-13	0.38	-0.48	1.57	5.44
Basic Earnings per Share	($0.22)	($0.21)	($0.20)	($0.20)	($0.17)	($0.18)	($0.08)	($0.07)	$0.01	($0.04)	($0.04)
Weighted Average Basic Shares Outstanding	204.78M	244.93M	221.13M	245.39M	310.84M	361.49M	320.03M	362.07M	363.29M	363.40M	363.05M
Diluted Earnings per Share	($0.22)	($0.21)	($0.20)	($0.20)	($0.17)	($0.18)	($0.08)	($0.07)	$0.01	($0.04)	($0.04)
Weighted Average Diluted Shares Outstanding	204.78M	244.93M	221.13M	245.39M	310.84M	361.49M	320.03M	362.07M	363.57M	363.40M	363.05M
Weighted Average Basic & Diluted Shares Outstanding	244.92M	244.92M	246.24M	246.24M	361.49M	361.49M	361.49M	363.18M	363.40M	363.40M	423.68M

This table details how cash moves in and out of Lexicon Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	66	-156	15	19	-44	90	-62	-18	-24	44	-3.33
Net Cash From Operating Activities	185	-176	-185	-149	114	-143	-87	-89	-162	-179	-68
Net Cash From Continuing Operating Activities	-159	-176	-185	-149	114	-142	-87	-89	-162	-179	-68
Net Income / (Loss) Continuing Operations	-4.68	-131	-123	-121	130	-59	-88	-102	-177	-200	-50
Consolidated Net Income / (Loss)	-4.68	-131	-123	-121	130	-59	-88	-102	-177	-200	-50
Depreciation Expense	0.73	2.06	3.40	3.68	3.65	2.93	0.29	0.43	0.55	0.53	0.62
Amortization Expense	0.52	0.53	0.60	1.34	1.47	1.01	0.05	0.74	-3.84	-7.46	-2.01
Non-Cash Adjustments To Reconcile Net Income	10	7.47	9.48	12	43	-118	11	12	16	14	11
Changes in Operating Assets and Liabilities, net	178	-54	-76	-45	-64	31	-10	0.40	2.66	14	-27
Net Cash From Investing Activities	-117	18	51	170	-156	381	2.11	-71	-50	-15	113
Net Cash From Continuing Investing Activities	-117	18	51	170	-156	381	2.11	-71	-50	-15	113
Purchase of Property, Plant & Equipment	-0.91	-0.23	-0.23	-0.10	-0.07	-0.09	-1.22	-1.33	-0.47	-1.03	0.00
Purchase of Investments	-326	-426	-268	-120	-322	-59	-34	-134	-223	-329	-140
Sale and/or Maturity of Investments	210	444	319	290	167	268	38	64	174	314	253
Net Cash From Financing Activities	-2.03	0.99	150	-2.24	-2.23	-148	23	142	188	238	-48
Net Cash From Continuing Financing Activities	-2.03	0.99	150	-2.24	-2.23	-148	23	142	188	238	-48
Repayment of Debt	-1.86	-2.02	-2.28	-15	-1.29	-217	-12	0.00	0.00	-1.31	-48
Issuance of Debt	0.07	0.00	146	13	0.00	0.00	-	49	50	0.00	0.00
Issuance of Preferred Equity	-	-	-	-	-	-	-	0.00	0.00	241	0.00
Issuance of Common Equity	0.11	3.62	7.99	0.73	0.00	70	37	94	139	0.06	0.07
Other Financing Activities, net	-	-	-	-	-	-	-	-	-0.82	-1.73	-0.57
Cash Interest Paid	6.27	6.05	5.87	16	19	17	0.80	2.29	10	13	8.33

This table details how cash moves in and out of Lexicon Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Change in Cash & Equivalents	76	-81	1.35	74	-61	-1.07	32	-3.77	-13	28	-15
Net Cash From Operating Activities	-38	-42	-51	-55	-49	-54	-21	-44	17	-24	-17
Net Cash From Continuing Operating Activities	-38	-42	-51	-55	-49	-54	-21	-44	17	-24	-17
Net Income / (Loss) Continuing Operations	-45	-51	-50	-48	-53	-65	-34	-25	3.25	-13	-16
Consolidated Net Income / (Loss)	-45	-51	-50	-48	-53	-65	-34	-25	3.25	-13	-16
Depreciation Expense	0.14	0.15	0.15	0.14	0.14	0.13	0.13	0.18	0.18	0.15	0.12
Amortization Expense	0.27	-3.00	-1.39	-0.88	-2.79	-2.30	-1.49	-0.93	-0.81	-0.33	0.06
Non-Cash Adjustments To Reconcile Net Income	3.82	3.90	4.72	5.48	3.29	3.68	1.87	1.50	3.17	3.43	2.67
Changes in Operating Assets and Liabilities, net	2.56	7.85	-4.28	-11	4.25	9.69	12	-19	11	-14	-4.55
Net Cash From Investing Activities	-75	-39	52	-110	-12	53	54	41	15	52	4.83
Net Cash From Continuing Investing Activities	-75	-39	52	-110	-12	53	54	41	15	52	4.83
Purchase of Investments	-122	-72	-0.10	-183	-77	-43	-26	-65	-26	-27	-22
Sale and/or Maturity of Investments	48	33	52	73	65	96	80	106	41	79	27
Net Cash From Financing Activities	189	-0.21	-0.00	239	-0.01	-0.92	-0.10	-0.57	-45	-	-2.93
Net Cash From Continuing Financing Activities	189	-0.21	-0.00	239	-0.01	-0.92	-0.10	-0.57	-45	-	-2.93
Repayment of Debt	-	-	-	-0.40	-	-0.91	-0.00	0.00	-45	-	-3.00
Issuance of Common Equity	139	-0.21	-	0.09	0.00	-	-0.03	0.00	-	-	0.07
Cash Interest Paid	1.76	3.45	3.29	3.26	3.26	3.28	3.13	2.97	1.92	1.76	1.69

This table presents Lexicon Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	652	476	437	284	418	204	137	194	229	298	185
Total Current Assets	532	358	322	173	338	158	89	141	177	246	102
Cash & Equivalents	203	47	62	80	36	126	64	46	22	67	34
Short-Term Investments	318	300	249	80	236	26	23	92	148	171	62
Accounts Receivable	0.91	7.49	4.83	5.92	57	0.40	0.01	0.03	1.01	3.47	2.38
Inventories, net	-	0.00	1.95	4.68	4.24	0.00	0.00	0.00	0.38	0.23	0.28
Other Current Assets	10	3.88	4.43	2.67	5.32	5.05	2.16	2.48	5.13	4.53	3.00
Plant, Property, & Equipment, net	21	19	18	16	14	0.30	1.18	2.07	1.99	2.48	1.86
Total Noncurrent Assets	98	98	97	95	66	46	45	51	51	50	81
Goodwill	45	45	45	45	45	45	45	45	45	45	45
Other Noncurrent Operating Assets	0.43	0.46	0.43	0.29	1.66	1.23	0.00	6.82	6.35	5.20	37
Total Liabilities & Shareholders' Equity	652	476	437	284	418	204	137	194	229	298	185
Total Liabilities	366	318	368	311	301	47	23	77	136	152	77
Total Current Liabilities	123	165	105	37	65	47	22	23	32	45	21
Short-Term Debt	1.98	16	14	1.12	11	12	0.00	-	-	0.00	4.60
Accounts Payable	20	53	39	12	12	5.47	9.15	10	14	15	3.08
Accrued Expenses	25	32	12	21	42	30	13	13	17	30	13
Total Noncurrent Liabilities	243	154	263	274	235	0.61	1.19	54	105	107	57
Long-Term Debt	101	85	232	244	234	0.00	0.00	49	100	100	49
Other Noncurrent Operating Liabilities	14	0.81	0.29	0.24	1.10	0.61	1.19	5.42	5.27	6.92	7.17
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	286	157	68	-26	117	156	114	117	93	146	108
Total Preferred & Common Equity	286	157	68	-26	117	156	114	117	93	146	108
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	286	157	68	-26	117	156	114	117	93	146	108
Common Stock	1,398	1,411	1,436	1,448	1,462	1,561	1,609	1,709	1,863	2,118	2,130
Retained Earnings	-1,109	-1,250	-1,365	-1,472	-1,341	-1,400	-1,488	-1,590	-1,767	-1,967	-2,018
Treasury Stock	-2.75	-3.37	-1.90	-2.88	-3.82	-4.84	-7.52	-2.06	-2.89	-4.62	-5.19
Accumulated Other Comprehensive Income / (Loss)	-0.22	-0.20	-0.22	-0.01	0.08	-0.01	-0.01	-0.43	0.03	0.12	0.03

This table presents Lexicon Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025
Total Assets	317	276	417	373	321	298	226	206
Total Current Assets	264	223	365	321	269	246	145	123
Cash & Equivalents	102	21	96	36	35	63	21	50
Short-Term Investments	154	197	259	274	224	132	118	66
Accounts Receivable	0.69	0.32	1.53	2.62	2.90	47	2.18	2.33
Inventories, net	0.17	0.34	0.51	0.59	0.64	0.20	0.17	0.16
Other Current Assets	6.12	4.29	7.01	7.68	6.71	3.32	3.73	4.09
Plant, Property, & Equipment, net	2.20	2.13	1.84	1.95	2.14	2.31	2.13	1.98
Total Noncurrent Assets	51	51	51	51	50	50	78	81
Goodwill	45	45	45	45	45	45	45	45
Other Noncurrent Operating Assets	6.26	6.43	6.19	6.02	5.84	5.01	34	37
Total Liabilities & Shareholders' Equity	317	276	417	373	321	298	226	206
Total Liabilities	130	137	128	133	143	175	96	86
Total Current Liabilities	26	32	23	28	36	111	35	22
Accounts Payable	11	12	8.07	12	14	11	5.90	3.80
Accrued Expenses	16	20	15	16	22	13	11	14
Current Deferred Revenue	-	-	-	-	-	45	17	4.30
Total Noncurrent Liabilities	104	105	105	106	107	64	61	64
Long-Term Debt	99	99	100	99	100	59	56	57
Other Noncurrent Operating Liabilities	5.48	5.44	5.08	6.00	6.67	5.30	5.20	7.54
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	186	140	289	240	179	123	129	120
Total Preferred & Common Equity	186	140	289	240	179	123	129	120
Preferred Stock	0.00	0.00	0.02	0.00	0.00	0.00	0.00	0.00
Total Common Equity	186	140	289	240	179	123	129	120
Common Stock	1,856	1,860	2,109	2,113	2,116	2,121	2,124	2,127
Retained Earnings	-1,667	-1,717	-1,815	-1,869	-1,933	-1,993	-1,989	-2,002
Treasury Stock	-2.89	-2.89	-4.62	-4.62	-4.62	-5.19	-5.19	-5.19
Accumulated Other Comprehensive Income / (Loss)	-0.10	-0.11	-0.05	-0.19	0.35	0.03	-0.01	0.03

This table displays calculated financial ratios and metrics derived from Lexicon Pharmaceuticals' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2020	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	103,622,755.00	104,036,346.00	105,587,794.00	105,925,402.00	106,271,927.00	144,354,161.00	148,895,707.00	188,725,743.00	244,924,695.00	-	363,398,680.00
DEI Adjusted Shares Outstanding	103,622,755.00	104,036,346.00	105,587,794.00	105,925,402.00	106,271,927.00	144,354,161.00	148,895,707.00	188,725,743.00	244,924,695.00	-	363,398,680.00
DEI Earnings Per Adjusted Shares Outstanding	-0.05	-1.26	-1.16	-1.14	1.23	-0.41	-0.59	-0.54	-0.72	-	-0.14
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	1.03	-89	-33	-72	148	-33	-61	-71	-120	-138	-34
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-33.07%	40.93%	-19.91%	-	-42.57%	-62.42%	-56.03%	-21.19%
Earnings before Interest and Taxes (EBIT)	2.04	-125	-45	-100	145	-45	-87	-104	-177	-213	-42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3.29	-122	-41	-95	150	-41	-87	-102	-180	-220	-43
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	186	-134	-124	-128	116	41	0.00	-71	-115	-124	-91
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-133	-88	3.15	59	91	16	27	27	23	8.29	65
Increase / (Decrease) in Invested Capital	-185	45	91	55	32	-75	0.00	0.49	-4.75	-14	57
Book Value per Share	$2.76	$1.51	$0.58	($0.25)	$1.10	$1.33	$0.76	$0.62	$0.38	$0.40	$0.30
Tangible Book Value per Share	$1.81	$0.57	($0.24)	($1.14)	$0.50	$0.95	$0.46	$0.38	$0.20	$0.28	$0.17
Total Capital	389	259	314	219	362	168	114	166	193	246	162
Total Debt	103	101	246	245	245	12	0.00	49	100	100	54
Total Long-Term Debt	101	85	232	244	234	0.00	0.00	49	100	100	49
Net Debt	-418	-245	-65	85	-26	-141	-87	-90	-71	-138	-42
Capital Expenditures (CapEx)	0.58	0.23	-171	0.10	0.07	-171	1.22	1.33	0.47	1.03	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-110	-137	-80	-22	12	-30	-20	-21	-25	-37	-11
Debt-free Net Working Capital (DFNWC)	411	210	231	138	283	123	67	118	145	201	86
Net Working Capital (NWC)	409	193	217	137	272	111	67	118	145	201	81
Net Nonoperating Expense (NNE)	5.71	42	25	48	18	25	27	31	57	62	16
Net Nonoperating Obligations (NNO)	-418	-245	-65	85	-26	-141	-87	-90	-71	-138	-42
Total Depreciation and Amortization (D&A)	1.25	2.58	3.95	5.02	5.12	3.95	0.35	1.17	-3.29	-6.93	-1.39
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.05)	($1.36)	($1.23)	($1.14)	$1.23	($0.53)	$0.00	$0.00	($0.80)	($0.63)	($0.14)
Adjusted Weighted Average Basic Shares Outstanding	103.77M	104.32M	105.59M	106.27M	106.22M	110.84M	0.00	0.00	221.13M	320.03M	363.05M
Adjusted Diluted Earnings per Share	($0.05)	($1.36)	($1.23)	($1.14)	$1.16	($0.53)	$0.00	$0.00	($0.80)	($0.63)	($0.14)
Adjusted Weighted Average Diluted Shares Outstanding	103.77M	104.32M	105.59M	106.27M	116.75M	110.84M	0.00	0.00	221.13M	320.03M	363.05M
Adjusted Basic & Diluted Earnings per Share	($0.05)	($1.36)	($1.23)	($1.14)	$1.23	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	103.59M	103.86M	105.24M	105.83M	106.97M	144.35M	0.00	0.00	246.24M	361.49M	423.68M
Normalized Net Operating Profit after Tax (NOPAT)	3.55	-89	-125	-72	119	-125	-61	-71	-120	-138	-34
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from Lexicon Pharmaceuticals' official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
DEI Shares Outstanding	189,561,819.00	244,924,695.00	244,924,695.00	246,236,753.00	246,236,753.00	361,492,295.00	-	361,492,295.00	363,178,000.00	363,398,860.00	363,398,680.00
DEI Adjusted Shares Outstanding	189,561,819.00	244,924,695.00	244,924,695.00	246,236,753.00	246,236,753.00	361,492,295.00	-	361,492,295.00	363,178,000.00	363,398,860.00	363,398,680.00
DEI Earnings Per Adjusted Shares Outstanding	-0.24	-0.21	-0.20	-0.20	-0.22	-0.18	-	-0.07	0.01	-0.04	-0.04
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	-31	-35	-33	-32	-39	-45	-23	-18	3.74	-8.53	-10
Return On Investment Capital (ROIC_SIMPLE)	-	-	-16.98%	-8.16%	-11.41%	-16.01%	-9.31%	-8.03%	2.01%	-4.83%	-6.41%
Earnings before Interest and Taxes (EBIT)	-45	-51	-50	-48	-53	-65	-46	-25	3.25	-11	-9.35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-44	-53	-51	-49	-56	-67	-47	-26	2.62	-11	-9.17
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-27	-23	-28	-34	-40	-44	-8.61	-14	-13	-49	-67
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	28	20	23	33	30	20	8.29	29	47	61	65
Increase / (Decrease) in Invested Capital	-4.10	-11	-4.75	2.19	1.12	-0.31	-14	-4.25	17	41	57
Book Value per Share	$0.98	$0.57	$0.38	$1.17	$0.97	$0.49	$0.40	$0.34	$0.36	$0.33	$0.30
Tangible Book Value per Share	$0.75	$0.39	$0.20	$0.99	$0.79	$0.37	$0.28	$0.22	$0.23	$0.21	$0.17
Total Capital	285	239	193	389	339	278	246	224	186	177	162
Total Debt	99	99	100	100	99	100	100	101	56	57	54
Total Long-Term Debt	99	99	100	100	99	100	100	59	56	57	49
Net Debt	-158	-119	-71	-256	-210	-158	-138	-94	-83	-59	-42
Capital Expenditures (CapEx)	0.14	0.08	0.00	0.00	0.00	0.31	0.47	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-19	-27	-25	-14	-17	-26	-37	-18	-29	-15	-11
Debt-free Net Working Capital (DFNWC)	238	191	145	341	293	233	201	177	110	101	86
Net Working Capital (NWC)	238	191	145	341	293	233	201	135	110	101	81
Net Nonoperating Expense (NNE)	14	16	17	17	15	20	11	7.32	0.48	4.24	5.18
Net Nonoperating Obligations (NNO)	-158	-119	-71	-256	-210	-158	-138	-94	-83	-59	-42
Total Depreciation and Amortization (D&A)	0.42	-2.84	-1.24	-0.74	-2.65	-2.18	-1.36	-0.75	-0.64	-0.18	0.17
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.22)	($0.21)	($0.20)	($0.20)	($0.17)	($0.18)	($0.08)	($0.07)	$0.01	($0.04)	($0.04)
Adjusted Weighted Average Basic Shares Outstanding	204.78M	244.93M	221.13M	245.39M	310.84M	361.49M	320.03M	362.07M	363.29M	363.40M	363.05M
Adjusted Diluted Earnings per Share	$0.00	($0.21)	($0.20)	($0.20)	($0.17)	($0.18)	($0.08)	($0.07)	$0.01	($0.04)	($0.04)
Adjusted Weighted Average Diluted Shares Outstanding	244.92M	244.93M	221.13M	245.39M	310.84M	361.49M	320.03M	362.07M	363.57M	363.40M	363.05M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	244.92M	244.92M	246.24M	246.24M	361.49M	361.49M	361.49M	363.18M	363.40M	363.40M	423.68M
Normalized Net Operating Profit after Tax (NOPAT)	-31	-35	-33	-32	-39	-45	-23	-18	2.62	-8.53	-10
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-

Financials Breakdown Chart

Key Financial Trends

Here are key trends for Lexicon Pharmaceuticals (LXRX) based on the most recent quarterly statements (2025 data and surrounding years) to help investors gauge topline progress, profitability, and liquidity.

Revenue ramp in 2025: Q4 2025 revenue reached $72.78 million, up from $41.54 million in Q3 2025 and well above $26.56 million in Q4 2024, signaling a strong top‑line ramp.
Positive quarterly earnings in Q2 2025: Net income in Q2 2025 was $3.252 million with basic/diluted EPS of $0.01, marking a rare profitable quarter in the period.
Healthy liquidity on the books (mid-2025): Cash and short‑term investments totaled roughly $116 million on the Q3 2025 balance sheet (Cash $49.66M; Short‑Term Investments $66.29M), providing runway for R&D and operations.
Significant investing cash inflows in Q3 2025: Net cash from investing activities was positive at about $52.1 million, contributing to a net cash inflow for the quarter.
Manageable long‑term debt: Long‑term debt hovered around $56–58 million across 2025, indicating manageable leverage without large new issuance.
Stable equity base through 2025: Total equity hovered near $120–$129 million (e.g., $129.44M in Q2 2025 and $120.16M in Q3 2025), suggesting limited dilution relative to peers in the period.
Top-line growth versus profitability: While revenue is rising, the company continues to post net losses in most 2025 quarters (e.g., Q1 2025 and Q3/Q4 2025), so profitability remains a work in progress.
Operating cash flow remains negative: Operating cash flow was negative across 2025 quarters, indicating ongoing cash burn despite revenue growth.
4Q 2025 net income decline: Consolidated net income for Q4 2025 was −$15.53 million, highlighting continued quarterly losses.
Cash burn persistence in Q4 2025 cash flow: Net cash from operating activities in Q4 2025 was negative, underscoring ongoing cash burn even as the revenue ramp accelerates.

05/07/26 02:37 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Lexicon Pharmaceuticals' Financials

When does Lexicon Pharmaceuticals' financial year end?

According to the most recent income statement we have on file, Lexicon Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Lexicon Pharmaceuticals' net income changed over the last 10 years?

Lexicon Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$50.34 million in 2025, rising from -$4.68 million in 2015. The previous period was -$231.48 million in 2024. See where experts think Lexicon Pharmaceuticals is headed by visiting Lexicon Pharmaceuticals' forecast page.

What is Lexicon Pharmaceuticals' operating income?

Lexicon Pharmaceuticals' total operating income in 2025 was -$48.91 million, based on the following breakdown:

Total Gross Profit: $144.18 million
Total Operating Expenses: $205.49 million

How has Lexicon Pharmaceuticals' revenue changed over the last 10 years?

Over the last 10 years, Lexicon Pharmaceuticals' total revenue changed from $130.01 million in 2015 to $144.45 million in 2025, a change of 11.1%.

How much debt does Lexicon Pharmaceuticals have?

Lexicon Pharmaceuticals' total liabilities were at $77.45 million at the end of 2025, a 49.2% decrease from 2024, and a 78.8% decrease since 2015.

How much cash does Lexicon Pharmaceuticals have?

In the past 10 years, Lexicon Pharmaceuticals' cash and equivalents has ranged from $22.47 million in 2023 to $202.99 million in 2015, and is currently $34.33 million as of their latest financial filing in 2025.

How has Lexicon Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Lexicon Pharmaceuticals' book value per share changed from 2.76 in 2015 to 0.30 in 2025, a change of -89.3%.

Related Companies

Financial statements for NASDAQ:LXRX last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexicon Pharmaceuticals (LXRX) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Lexicon Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexicon Pharmaceuticals (LXRX) Financials

Annual Income Statements for Lexicon Pharmaceuticals

Quarterly Income Statements for Lexicon Pharmaceuticals

Annual Cash Flow Statements for Lexicon Pharmaceuticals

Quarterly Cash Flow Statements for Lexicon Pharmaceuticals

Annual Balance Sheets for Lexicon Pharmaceuticals

Quarterly Balance Sheets for Lexicon Pharmaceuticals

Annual Metrics And Ratios for Lexicon Pharmaceuticals

Quarterly Metrics And Ratios for Lexicon Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Lexicon Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools